SLC27A5 Antibody - #DF3845

(4)   (5)  
Product: SLC27A5 Antibody
Catalog: DF3845
Description: Rabbit polyclonal antibody to SLC27A5
Application: WB IHC IF/ICC
Cited expt.: WB
Reactivity: Human, Mouse, Rat
Prediction: Bovine, Horse
Mol.Wt.: 75 KD; 75kD(Calculated).
Uniprot: Q9Y2P5
RRID: AB_2836202

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MS Report
HPLC Report
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
WB 1:500-1:1000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Prediction:
Bovine(91%), Horse(91%)
Clonality:
Polyclonal
Specificity:
SLC27A5 Antibody detects endogenous levels of total SLC27A5.
RRID:
AB_2836202
Cite Format: Affinity Biosciences Cat# DF3845, RRID:AB_2836202.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

ACSB; ACSVL6; BA CoA ligase; BA-CoA ligase; BACS; BAL; Bile acid CoA ligase; Bile acid-CoA ligase; Bile acyl CoA synthetase; Bile acyl-CoA synthetase; Cholate CoA ligase; Cholate--CoA ligase; FACVL3; FATP 5; FATP-5; FATP5; Fatty acid Coenzyme A ligase very long chain 3; Fatty acid transport protein 5; Fatty-acid-coenzyme A ligase; FLJ22987; S27A5_HUMAN; Slc27a5; Solute carrier family 27 (fatty acid transporter) member 5; Solute carrier family 27 member 5; Very long chain acyl CoA synthetase homolog 2; Very long chain acyl CoA synthetase related protein; very long-chain 3; Very long-chain acyl-CoA synthetase homolog 2; Very long-chain acyl-CoA synthetase-related protein; VLACS related; VLACS-related; VLACSR; VLCS H2; VLCS-H2; VLCSH2;

Immunogens

Immunogen:

A synthesized peptide derived from human SLC27A5, corresponding to a region within the internal amino acids.

Uniprot:

Q9Y2P5(S27A5_HUMAN) >>Visit HPA database.

Gene(ID):
SLC27A5(10998)
Expression:
Q9Y2P5 S27A5_HUMAN:

Predominantly expressed in liver.

Sequence:
MGVRQQLALLLLLLLLLWGLGQPVWPVAVALTLRWLLGDPTCCVLLGLAMLARPWLGPWVPHGLSLAAAALALTLLPARLPPGLRWLPADVIFLAKILHLGLKIRGCLSRQPPDTFVDAFERRARAQPGRALLVWTGPGAGSVTFGELDARACQAAWALKAELGDPASLCAGEPTALLVLASQAVPALCMWLGLAKLGCPTAWINPHGRGMPLAHSVLSSGARVLVVDPDLRESLEEILPKLQAENIRCFYLSHTSPTPGVGALGAALDAAPSHPVPADLRAGITWRSPALFIYTSGTTGLPKPAILTHERVLQMSKMLSLSGATADDVVYTVLPLYHVMGLVVGILGCLDLGATCVLAPKFSTSCFWDDCRQHGVTVILYVGELLRYLCNIPQQPEDRTHTVRLAMGNGLRADVWETFQQRFGPIRIWEVYGSTEGNMGLVNYVGRCGALGKMSCLLRMLSPFELVQFDMEAAEPVRDNQGFCIPVGLGEPGLLLTKVVSQQPFVGYRGPRELSERKLVRNVRQSGDVYYNTGDVLAMDREGFLYFRDRLGDTFRWKGENVSTHEVEGVLSQVDFLQQVNVYGVCVPGCEGKVGMAAVQLAPGQTFDGEKLYQHVRAWLPAYATPHFIRIQDAMEVTSTFKLMKTRLVREGFNVGIVVDPLFVLDNRAQSFRPLTAEMYQAVCEGTWRL

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Horse
91
Bovine
91
Pig
73
Sheep
73
Rabbit
73
Dog
0
Xenopus
0
Zebrafish
0
Chicken
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

Research Backgrounds

Function:

Acyl-CoA synthetase that catalyzes the activation of bile acids via formation of bile acid CoA thioesters which is necessary for their subsequent conjugation with glycine or taurine. Both primary bile acids (cholic acid and chenodeoxycholic acid) and secondary bile acids (deoxycholic acid and lithocholic acid) are the principal substrates. Also exhibits acyl CoA synthetase activity that activates very long-chain fatty acids (VLCFAs) by catalyzing the formation of fatty acyl-CoA. In vitro, also activates 3-alpha,7-alpha,12-alpha-trihydroxy-5-beta-cholestanate (THCA), the C27 precursor of cholic acid deriving from the de novo synthesis from cholesterol. Exhibits long-chain fatty acids (LCFA) transport activity. Plays an important role in hepatic fatty acid uptake and bile acid reconjugation and recycling but not in de novo synthesis of bile acids (By similarity).

Subcellular Location:

Endoplasmic reticulum membrane>Multi-pass membrane protein. Microsome. Cell membrane>Multi-pass membrane protein.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Predominantly expressed in liver.

Family&Domains:

Belongs to the ATP-dependent AMP-binding enzyme family.

Research Fields

· Human Diseases > Endocrine and metabolic diseases > Insulin resistance.

· Metabolism > Lipid metabolism > Primary bile acid biosynthesis.

· Metabolism > Global and overview maps > Metabolic pathways.

· Organismal Systems > Endocrine system > PPAR signaling pathway.

References

1). B-cell lymphoma 6 alleviates nonalcoholic fatty liver disease in mice through suppression of fatty acid transporter CD36. Cell death & disease, 2022 (PubMed: 35436984) [IF=8.1]

Application: WB    Species: Mouse    Sample:

Fig. 5: Overexpression of BCL6 hampers CD36 expression both in vivo and in vitro. Relative mRNA levels of genes related to (A) FFA oxidation, (B) synthesis, and (C) uptake in the livers of AAV-Control mice and the AAV-BCL6 mice fed an HFD for 16 weeks. D Protein level of BCL6 and genes related to FFA uptake in the livers of mice. Relative mRNA levels of gene related to (E) FFA oxidation, (F) synthesis and G uptake in the livers of AAV-Control mice and the AAV-BCL6 mice fed an HFD for 16 weeks. D Protein level of BCL6 and genes related to FFA uptake in the livers of mice. Relative mRNA levels of gene related to (E) FFA oxidation, (F) synthesis, and (G) uptake in the LO2 cells stimulated with PA (0.3 mM) for 24 h after transfected with Ad-GFP or Ad-BCL6 for 48 h. n = 3 in each group. H Protein level of BCL6 and genes related to FFA uptake in the LO2 cells. Data represent the mean ± SEM, *P 
2). Norepinephrine inhibits CD8+ T-cell infiltration and function, inducing anti-PD-1 mAb resistance in lung adenocarcinoma. British journal of cancer, 2023 (PubMed: 36646807) [IF=6.4]

Application: WB    Species: human    Sample: LUAD cells

Fig. 5: Norepinephrine (NE) regulates the secretion of CXCL9 and adenosine (ADO) by WNT7A/β-catenin signalling in lung adenocarcinoma (LUAD) cells. a The KEGG pathway enrichment analysis of the differentially expressed genes (DEGs); b the GSEA between the NE and the control (NC) groups; c the volcano plots of the DEGs; d the expression levels of Wnt1, Wnt2, Wnt3a, Wnt4, Wnt5a, Wnt6, Wnt7a and Wnt10a in the tumour tissues of the anti-PD-1 mAb + Vehicle and NE + anti-PD-1 mAb + Vehicle groups; e western blotting confirmed the efficiency of WNT7A silencing; f downregulation of WNT7A by shRNA significantly antagonised NE-induced β-catenin, CD39 and CD73 expression, as well as NE-inhibited CXCL9 expression in LUAD cells; g downregulation of β-catenin by shRNA greatly antagonised NE/WNT7A-induced CD39 and CD73 expression, as well as NE/WNT7A-inhibited CXCL9 expression in LUAD cells; h the β-catenin expression level in tumours was detected in the anti-PD-1 mAb + vehicle group and anti-PD-1 mAb+NE + vehicle group using immunohistochemistry. *P 
3). Over-Expression and Prognostic Significance of FATP5, as a New Biomarker, in Colorectal Carcinoma. Frontiers in Molecular Biosciences, 2022 (PubMed: 35155561) [IF=5.0]
4). Identification of key genes associated with the progression of liver fibrosis to hepatocellular carcinoma based on iTRAQ proteomics and GEO database. Annals of hepatology, 2022 (PubMed: 35124283) [IF=3.7]

Application: WB    Species: human    Sample:

Fig. 8. The expression and survival analysis of ALDH2, SLC27A5 and ASNS in patients with HCC and validation. (A) The expression of ALDH2, SLC27A5 and ASNS in HCC. (B) The expression of ALDH2, SLC27A5 and ASNS in different stages of HCC. (C) Survival analysis of ALDH2, SLC27A5 and ASNS. (D) WB analysis of ALDH2, SLC27A5 and ASNS. (E) qRT-PCR analysis of ALDH2, SLC27A5 and ASNS.

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.